Pain R&D Firms Target Nerve Cell Signaling In Hunt For Potent Non-Opioids
Executive Summary
The prospect of potent analgesia without opiate side effects is encouraging a groundswell of R&D focusing on pain drugs that specifically target nerve cell signaling without affecting other body systems
You may also be interested in...
Elan Prialt Clears FDA; Half Of Projected Market Does Not Have Delivery Pump
Elan estimates that more than half of the 120,000 potential users of its non-opioid analgesic Prialt do not already possess an internal drug delivery pump expected to be used in ziconotide administrations
Elan Prialt Clears FDA; Half Of Projected Market Does Not Have Delivery Pump
Elan estimates that more than half of the 120,000 potential users of its non-opioid analgesic Prialt do not already possess an internal drug delivery pump expected to be used in ziconotide administrations
Elan Prialt NDA Awaits Longer-Term Data In Chronic Pain
Elan is planning a long-term study of the chronic pain treatment Prialt (ziconotide) to supplement its pending NDA, the company told a Feb. 4 conference call